ABBOTT LABORATORIES 8-K

What Happened

• Abbott Laboratories filed an 8-K reporting that on February 23, 2026 it entered into a pricing agreement with Morgan Stanley, Barclays, BofA Securities and J.P. Morgan (and other underwriters) to issue $20.0 billion in senior notes. The offering includes one $1.0 billion floating-rate tranche and eight fixed-rate tranches with various maturities and coupons. The sale is expected to close on March 9, 2026, subject to customary closing conditions. Abbott said net proceeds, together with cash on hand or other borrowings, will be used to fund the proposed acquisition of Exact Sciences, repay certain Exact Sciences indebtedness, pay related fees and expenses, and for general corporate purposes.

Key Details

• Total offering: $20,000,000,000 aggregate principal amount of senior notes.
• Tranche breakdown (amount, coupon, maturity):
  • $1.0B Floating Rate Notes due 2029
  • $2.25B 3.700% Notes due 2029
  • $2.50B 4.000% Notes due 2031
  • $2.75B 4.300% Notes due 2033
  • $3.75B 4.650% Notes due 2036
  • $2.00B 4.750% Notes due 2038
  • $3.75B 5.500% Notes due 2056
  • $2.00B 5.600% Notes due 2066
• Pricing agreement dated Feb 23, 2026; Prospectus Supplement filed Feb 25, 2026; closing expected March 9, 2026.

Why It Matters

• This is a large debt financing tied directly to Abbott’s planned acquisition of Exact Sciences; proceeds will be used to fund the deal and refinance Exact Sciences’ debt.
• The issuance will increase Abbott’s outstanding debt and future interest obligations by up to $20 billion, which investors should weigh alongside the strategic benefits of the acquisition.
• Closing is subject to customary conditions and forward-looking risks disclosed in Abbott’s filings; investors should review the Prospectus Supplement and Abbott’s risk factors for more details.